Inari Medical, Inc. (NASDAQ:NARI) Stock Holdings Lifted by Jane Street Group LLC

Jane Street Group LLC lifted its position in Inari Medical, Inc. (NASDAQ:NARI) by 32.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 95,223 shares of the company’s stock after acquiring an additional 23,286 shares during the quarter. Jane Street Group LLC’s holdings in Inari Medical were worth $3,927,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after purchasing an additional 435 shares during the period. GAMMA Investing LLC raised its position in Inari Medical by 67.2% during the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after buying an additional 473 shares during the period. KBC Group NV lifted its stake in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after acquiring an additional 522 shares during the period. Finally, Covestor Ltd grew its stake in Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after acquiring an additional 926 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Buying and Selling

In related news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now owns 445,310 shares in the company, valued at $22,265,500. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the sale, the director now owns 441,233 shares of the company’s stock, valued at $24,559,028.78. This trade represents a 11.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 203,000 shares of company stock worth $10,362,000. 10.60% of the stock is currently owned by insiders.

Inari Medical Stock Performance

NARI opened at $55.03 on Thursday. The company has a market cap of $3.22 billion, a PE ratio of -40.76 and a beta of 0.97. The stock has a 50-day moving average of $49.30 and a 200-day moving average of $48.04. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.10.

Analysts Set New Price Targets

NARI has been the subject of a number of research analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Robert W. Baird increased their target price on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 29th. Canaccord Genuity Group boosted their price target on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. Leerink Partnrs upgraded Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Finally, Stifel Nicolaus initiated coverage on Inari Medical in a research note on Tuesday, September 17th. They issued a “hold” rating and a $50.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $61.80.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.